Replies to post #16466 on DNAprint Genomics (DNAG)

[Gcbr]

W2P---This was the part I liked.

"Globally, healthcare is undergoing a profound transformation toward targeted therapeutics and treatment regimens. Working with our Business Partners, IBM is deeply committed to shedding light on the critical role information technology will play in personalized medicine," said Mike Svinte, vice president, information-based medicine, IBM. "

JMHO

Take Care
Arch

[Gcbr]

W2P---what I find interesting is this cancer

A primary area of focus for the program is colorectal cancer, where DNAPrint will work with primary investigator Dr. Timothy Yeatman, Moffitt’s Associate Center Director for Clinical Investigations.

Remember when Scott tried to get a shell going to help Doc T?

I think Doc T has some special insight into this type of cancer. JMHO of course.

Take Care
Arch

[eb0783]

"involved in 24 clinical trials at Moffit . . . "

W2P: We need to ask DNAP to post the presentation they gave us at the meeting to their website. The presentation has that kind of info but I couldn't take many notes while I was standing up. Posting it and making it available to everyone should not be a problem and it would even better fit the Sarbane-Oxley requirements of giving everyone the same information. Plenty of other companies post the presentations, that they give stockholders at their annual meetings, on their websites.

I just emailed them with that request. Maybe it would help if a number of us requested it.

Paul

[Easyman51]

Arch, W2P; sounds to me like Moffit is a cross roads where
IBM's Big Gene & DnaPrint's ADMIXMAP get to hitchhike off each other. No doubt the effectiveness of our proprietary information will be monitored and you can bet that IBM will know. Ahhhhh, recognition sometimes comes after all other attemts by competitors are eclipsed. Tony says he's in the "pole possition", and this was only a month or so ago.

I BELIEVE! :>)

Peace/Boat Drinks